Progress through Partnership
Message from Chair of the Board and Executive Director
We have evolved, expanded, and adapted. Our mission, however, remains unchanged: to bring the best science to neglected patients, by discovering and developing new treatments for diseases where commercial R&D is not enough.
DNDi in Numbers
7 treatments delivered since 2003
More than 3,000 people trained since 2010
4 clinical research platforms and networks in disease-endemic countries since 2003
590,170 people screened for sleeping sickness in DRC in 2016
More than 430 million ASAQ treatments for malaria distributed since 2007
Recommended in 2016 by WHO Superbooster Therapy for Paediatric HIV/TB
new chemical entities in DNDi's R&D pipeline in 2016
388,461 compounds screened in 2016
in-kind contributions from partners since 2007
722 people working for DNDi in partner organizations in 2016
Nomination of 3 pre-clinical candidates (for leishmaniasis and filarial diseases) in 2016
5 universities from the UK, the US, and India joined the Open Synthesis Network in 2016
R & D
Click on the icons below to find out about the diseases DNDi is researching and the status of our R&D projects:
GARDP launched with three programmes starting for drug-resistant infections
Building on DNDi’s experience in developing a research & development pipeline for neglected diseases, the Global Antibiotic Research & Development Partnership was officially launched in May 2016. A joint initiative between WHO and DNDi, with seed funding from Germany, the UK, Switzerland, the Netherlands, South Africa, and Médecins Sans Frontières, GARDP’s vision is a world where everyone in need of antibiotics receives effective, appropriate, and affordable treatment, irrespective of where they live.
How has drug discovery at DNDi evolved over the past decade?
Dr Robert Don reflects on challenges and achievements in drug discovery at DNDi over the last 12 years.
What norms and principles should govern the financing of health R&D?
The need for alternative models such as DNDi, to boost innovation and access for neglected tropical diseases, where the commercial model clearly fails to meet the needs of patients in low- and middle-income countries, has long been recognized. But in recent years, the global environment has evolved.
Strengthening endemic country capacity to advance new treatments
Since its inception in 2003, DNDi has worked to integrate capacity strengthening into its projects in a sustainable manner, through knowledge sharing and technology transfers. The objective is to increase the chances of registration, uptake, and sustainable access of new treatments for neglected diseases and, ultimately, to support the transfer of ownership to disease-endemic countries.
The challenge of conducting clinical studies in remote areas
Because sleeping sickness occurs in very remote areas of the DRC, there are major operational challenges that need to be overcome to conduct clinical studies.
In Colombia, stakeholders from Government, academia, NGOs, and patient organizations are working in partnership with DNDi aiming to eliminate barriers to diagnosis and treatment for Chagas disease in the country for its estimated 437,000 patients.
An unattainable cure: Countries rich, poor, and in the middle, all struggling to access HCV drugs
The powerful generation of new direct-acting antivirals to treat HCV have become the poster child for the prohibitive price of medicines in many countries. New treatment regimens combining DAAs cost upwards of USD 100,000 in the US, and EUR 40,000 in European countries.
Photo credits: DNDi/Neil Brandvold, DNDi/Paul Kamau, Shutterstock/iStock, DNDi/Kishore Pandit, DNDi/Fabio Nascimento, DNDi/Abraham Ali/Imageworks, DNDi/João Roberto Ripper.